Eli Lilly ( LLY 1.32%) is now known for its weight loss drugs. Its stock has risen 150% since mid-2022 because of high demand for Mounjaro (tirzepatide approved to treat type 2 diabetes) and Zepbound ...
Eli Lilly’s new GLP-1 drug and diversified R&D pipeline could drive healthcare sector inflows and deliver over 40% upside.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback